Under construction – not a live service
Sign in
Taking people in SpainPhase 3

Long-term follow-up of patients with relapsed T-cell leukemia or lymphoma treated with OC-1 cells

Follows people with relapsed T-cell leukemia or lymphoma after OC-1 cell treatment for 15 years.

Key facts

Who runs it
Onechain Immunotherapeutics S.L.
Where
Barcelona and Esplugues de Llobregat, SpainSee the 2 sites
Registry title
Long-term Follow-up study for relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL) patients previously treated with OC-1 cells.
Status
Recruiting
Phase
Phase 3
People taking part
20 people, planned
Started
21 May 2025
Expected to end
3 Feb 2040
Type of study
Interventional
Record updated
11 April 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with relapsed or hard-to-treat T-cell acute lymphoblastic leukemia or lymphoma who already received OC-1 cells. They are followed for 15 years to watch for late side effects.

Sex
Both men and women can join.
Disease stage
Relapsed or refractory (not responding to treatment) CD1a-positive T-cell acute lymphoblastic leukemia or lymphoma.
Earlier treatment
People must already have received at least one fraction of the OC-1 cell investigational product.
Biomarker or test result
The disease must be CD1a-positive.

Main reasons for not taking part

  • The record lists no exclusions; all people who received OC-1 cells can join.

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Patients previously treated with at least one fraction of OC-1 cell investigational product
  • Patient or patient’s legal representative has provided signed and dated informed consent
  • Patient is able to comply with the study requirements

Who cannot take part

  • None. All patients who have received prior treatment with OC-1 cell investigational product are eligible for this long-term follow up (LTFU) study

Where in Spain

  • Hospital Clinic de BarcelonaBarcelona, SpainTaking people
  • Hospital Sant Joan De Deu BarcelonaEsplugues de Llobregat, SpainTaking people

About the trial

What the trial wants to find out

To monitor patients with primary relapsed/refractory (R/R) CD1a-positive T-ALL/LL who received OC-1 cells, for 15 years following CAR-T infusion to assess the risk of delayed adverse events (AEs).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Long-term Follow-up study for relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL) patients previously treated with OC-1 cells.
Plain-language title
Long-term follow-up of patients with relapsed T-cell leukemia or lymphoma treated with OC-1 cellsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
11 April 2025